9th June 2022 | Pharma Updates
India's 'digital vaccine' that prevent real-world health problems granted the first global patent
Bhargav Sri Prakash, an Indian biomedical tech entrepreneur and the founder of Friends Learn, has been granted the world’s first patent for a ‘digital vaccine, ‘ a platform that uses a metaverse to prevent real-world health problems.
Lupin receives approval from USFDA for a generic drug
Lupin announced on Monday that it has received approval from the US Food and Drug Administration to market Tenofovir Alafenamide tablets, which are used to treat chronic hepatitis B virus infection.
With its first global approval, Roche's Lunsumio enters the CAR-T therapy
Lunsumio, or mosunetuzumab, has received conditional European Commission approval to treat follicular lymphoma patients who have had at least two prior therapies. Lunsumio is the first CD20xCD3 bispecific antibody to be approved anywhere.
Biocon Biologics anticipates significant benefits from Viatris acquisition and SII deal
Biocon Biologics expects to earn $1.8 billion in FY24, thanks to the integration of Viatris’ biosimilars business, a vaccines alliance with Serum Institute of India (SII), and the scaling up of its domestic and emerging markets biosimilars business.
India interested in Japanese medicaltechnology
As part of a five-year $42 billion investment and financing package agreed by Prime Ministers Fumio Kishida of Japan and Narendra Modi in March, India is looking to leverage its partnership with Japan to manufacture medical equipment.
Novavax's protein-based Covid shot approved by FDA's advisory committee
The advisory committee for FDA has recommended that regulators approve Novavax’s protein-based Covid shot. In India and Thailand, the vaccine is already approved for adolescents.
Merck expects more than 80 potential oncology approvals by 2028, led by Keytruda
Merck & Co. wasn’t exactly a major oncology player prior to the introduction of Keytruda. The New Jersey pharma is looking to solidify its position as the world’s best-selling cancer drug. From now until 2028, Merck has a chance to secure over 80 oncology approvals.
